Review Article

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors

Figure 2

(a)–(c) Planar scans of the abdomen, 3 days after the injection of 200 mCi 177Lu-octreotate in a patient with liver metastases of an operated neuroendocrine pancreatic tumor. (a) After the first treatment; (b) after the second treatment; (c) after the fourth treatment. Note the loss of intensity of uptake in the liver lesions (arrows in (a)). This sign virtually always indicates a tumor volume response. (d) and (e). CT scans of the same patient: (d) before treatment; (e) 3 months after the last treatment. Tumor (arrows in (d)) is not demonstrated on (e). Neither MRI nor octreoscan could demonstrate definite tumor deposits at that time [66].
102819.fig.002a
(a)
102819.fig.002b
(b)
102819.fig.002c
(c)
102819.fig.002d
(d)
102819.fig.002e
(e)